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Reliability of simple capillaroscopic definitions in
describing capillary morphology in rheumatic dis-
eases
Rheumatology key message
. The optimized simple definitions for normal and
abnormal capillary morphology provide excellent
reliability.
SIR, Nailfold capillaroscopy is emerging as a widely used
tool to investigate the microvasculopathy in rheumatic
diseases [1]. Through (semi-)quantitative and qualitative
assessments of capillaroscopic images, valuable informa-
tion on disease progression and outcome can be obtained
[26]. In the literature, however, a variety of definitions are
used to describe capillaroscopic findings of single capil-
laries, which hampers the interpretation of results in clinics
and the interpretation of advancements made in research.
One objective of the EULAR Study Group on
Microcirculation in Rheumatic Diseases is to standardize
and simplify the definitions used in describing capillaro-
scopic findings. In a first pilot study by the EULAR Study
Group on Microcirculation in Rheumatic Diseases, a
simple definition was proposed to describe the morph-
ology of single capillaries as being normal or abnormal
[7]. A moderate reliability of this definition was obtained
between attendees of the sixth EULAR capillaroscopy
course, held in Genoa, Italy in 2014. Attendees were
rheumatologists with varying levels of expertise in per-
forming capillaroscopy (of which the majority were nov-
ices). Subsequently, to further fine tune the previously
proposed definition, convexity of the capillary head as a
conditional criterion for normal capillary morphology was
added (see Fig. 1). This optimized definition of the morph-
ology of single capillaries was subsequently evaluated at
the seventh EULAR capillaroscopy course, held in Genoa
in 2016. Thirty images with good visibility of single capil-
laries were presented to the attendees of the course
(n=119). Attendees were asked to classify the 30 single
capillaries (one highlighted capillary per capillaroscopic
image) as having a normal or abnormal morphology.
They were also asked to categorize themselves into one
of the following levels of expertise in capillaroscopy: no
experience (novices), n=69; <5 years of experience,
n=41 and >5 years of experience, n=9. In addition, five
independent experts (A.H., F.I., A.S., M.C. and V.S.) eval-
uated the capillaries. The assessment of V.S. was con-
sidered as the gold standard. Interrater agreement was
evaluated by calculation of Cohen’s k between each
rater pair of all possible combinations of attendees and
the gold standard and then averaged to provide the light k
[8]. Furthermore, the Cohen’s k scores between each at-
tendee and the gold standard were averaged to obtain a
mean index of reliability of the attendees to the gold
standard. Finally, mean proportions of overall and specific
agreement of attendees compared with the gold standard
were reported. The study was conducted with the ap-
proval of the ethical committee of the Ghent University
(EC2008/385).
The resulting light k based on 30 capillaries was 0.78
for all EULAR course attendees and 0.82 for the five
independent experts. More specifically, the light k was
0.84 for experienced attendees, 0.78 for moderately
experienced attendees and 0.77 for novices. The mean
Cohen’s k coefficient of all attendees to the gold stand-
ard was 0.81 (95% CI 0.79, 0.83), with a mean propor-
tion of overall agreement of 91%, a mean proportion of
specific agreement for abnormal of 89% and for normal
of 92%. Subgroup analyses according to the level of
experience resulted in similar results for both reliability
and agreement measures. Subgroup analyses demon-
strated a mean Cohen’s k between each attendee and
the gold standard of 0.83 (95% CI 0.78, 0.88) for experi-
enced attendees, 0.81 (95% CI 0.77, 0.85) for moder-
ately experienced attendees and 0.80 (95% CI 0.77,
0.83) for novices. Differences in mean agreement pro-
portions between the subgroups and the total group of
attendees were negligible. The mean Cohen’s k be-
tween each expert in capillaroscopy and the gold stand-
ard was 0.81 (95% CI 0.71, 0.92), with a mean
proportion of overall agreement of 91%, a mean propor-
tion of specific agreement for abnormal of 89% and for
normal of 92%.
In conclusion, this multicentre, international study, con-
ducted at the seventh EULAR course on capillaroscopy,
demonstrated that the reliability of the optimized simple
capillaroscopic definition of normal and abnormal
morphologies of capillaries is excellent, even when used
by rheumatologists with varying levels of expertise in
capillaroscopy. Further, large-scale validation with
random selection of single capillaries is needed to validate
these findings.
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FIG. 1 Evaluation of single capillary morphology
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